FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2765300930> ?p ?o ?g. }

• W2765300930 endingPage "e31" @default.
• W2765300930 startingPage "e25" @default.
• W2765300930 abstract "BackgroundMethicillin-resistant Staphylococcus aureus (MRSA) is a prevalent pathogen in patients with cystic fibrosis (CF) associated with increased morbidity. Ceftaroline fosamil is an intravenous (IV) cephalosporin with activity against MRSA. There are minimal data regarding dosing in the CF population. The objective of this study was to determine the pharmacokinetic and pharmacodynamic profile of IV ceftaroline in patients with CF.MethodsWe conducted a single-center prospective study of children and young adults with CF receiving ceftaroline (15 mg/kg IV up to 600 mg every 8 h) as part of treatment for a CF pulmonary exacerbation between June 2016 and April 2017. Seven patients were enrolled for a total of 10 treatment courses. For each treatment course, up to 8 plasma samples were assayed for ceftaroline using ultra-high performance liquid chromatography with mass spectrometry. Maximum plasma concentration, systemic clearance, and elimination half-life were calculated. The area under the curve (AUC) above the minimum inhibitory concentration (MIC) and the percent time above the MIC (%fT > MIC) were determined for each subject using MICs of 0.5, 1, and 2 μg/mL and the measured MIC if available.ResultsThe mean (SD) age for the 7 patients was 20.3 (8.0) years. Mean (SD) maximum plasma concentration of ceftaroline was 22.7 (9.6) μg/mL, systemic clearance 7.9 (3.3) L/h, and half-life 1.1 (0.4) hours. Using a MIC of 1 μg/mL, accepted as the MIC 90 of MRSA isolates, AUC above MIC mean (SD) was 53.6 (19.5) μg·h/mL, mean (SD) %fT > MIC was 75.7 (10.4), and all subjects had >60%fT > MIC.ConclusionsIn this cohort of CF patients, mean ceftaroline half-life was 1.1 h, which is notably lower than the general population. The dosing regimen studied, which exceeds the recommended dosing in the non-CF population, was adequate to achieve >60% time above the MIC in all patients." @default.
• W2765300930 created "2017-11-10" @default.
• W2765300930 creator A5011723155 @default.
• W2765300930 creator A5020868135 @default.
• W2765300930 creator A5036247714 @default.
• W2765300930 creator A5051188293 @default.
• W2765300930 creator A5052028096 @default.
• W2765300930 creator A5062382858 @default.
• W2765300930 creator A5068011640 @default.
• W2765300930 creator A5086628162 @default.
• W2765300930 date "2018-05-01" @default.
• W2765300930 modified "2023-10-18" @default.
• W2765300930 title "Ceftaroline pharmacokinetics and pharmacodynamics in patients with cystic fibrosis" @default.
• W2765300930 cites W1553852975 @default.
• W2765300930 cites W1954257474 @default.
• W2765300930 cites W1985717850 @default.
• W2765300930 cites W2001645578 @default.
• W2765300930 cites W2008297511 @default.
• W2765300930 cites W2036439055 @default.
• W2765300930 cites W2055414921 @default.
• W2765300930 cites W2059953204 @default.
• W2765300930 cites W2066510676 @default.
• W2765300930 cites W2071260810 @default.
• W2765300930 cites W2099449365 @default.
• W2765300930 cites W2105534700 @default.
• W2765300930 cites W2111224882 @default.
• W2765300930 cites W2116388403 @default.
• W2765300930 cites W2117107959 @default.
• W2765300930 cites W2123796047 @default.
• W2765300930 cites W2125226736 @default.
• W2765300930 cites W2143313542 @default.
• W2765300930 cites W2230229972 @default.
• W2765300930 cites W2338827971 @default.
• W2765300930 cites W2465697526 @default.
• W2765300930 doi "https://doi.org/10.1016/j.jcf.2017.10.010" @default.
• W2765300930 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29103924" @default.
• W2765300930 hasPublicationYear "2018" @default.
• W2765300930 type Work @default.
• W2765300930 sameAs 2765300930 @default.
• W2765300930 citedByCount "14" @default.
• W2765300930 countsByYear W27653009302019 @default.
• W2765300930 countsByYear W27653009302020 @default.
• W2765300930 countsByYear W27653009302021 @default.
• W2765300930 countsByYear W27653009302022 @default.
• W2765300930 countsByYear W27653009302023 @default.
• W2765300930 crossrefType "journal-article" @default.
• W2765300930 hasAuthorship W2765300930A5011723155 @default.
• W2765300930 hasAuthorship W2765300930A5020868135 @default.
• W2765300930 hasAuthorship W2765300930A5036247714 @default.
• W2765300930 hasAuthorship W2765300930A5051188293 @default.
• W2765300930 hasAuthorship W2765300930A5052028096 @default.
• W2765300930 hasAuthorship W2765300930A5062382858 @default.
• W2765300930 hasAuthorship W2765300930A5068011640 @default.
• W2765300930 hasAuthorship W2765300930A5086628162 @default.
• W2765300930 hasBestOaLocation W27653009301 @default.
• W2765300930 hasConcept C111113717 @default.
• W2765300930 hasConcept C112705442 @default.
• W2765300930 hasConcept C126322002 @default.
• W2765300930 hasConcept C176947019 @default.
• W2765300930 hasConcept C2776938444 @default.
• W2765300930 hasConcept C2777014857 @default.
• W2765300930 hasConcept C2777288759 @default.
• W2765300930 hasConcept C2908647359 @default.
• W2765300930 hasConcept C501593827 @default.
• W2765300930 hasConcept C64778159 @default.
• W2765300930 hasConcept C71924100 @default.
• W2765300930 hasConcept C76318530 @default.
• W2765300930 hasConcept C86803240 @default.
• W2765300930 hasConcept C89423630 @default.
• W2765300930 hasConcept C90924648 @default.
• W2765300930 hasConcept C98274493 @default.
• W2765300930 hasConcept C99454951 @default.
• W2765300930 hasConceptScore W2765300930C111113717 @default.
• W2765300930 hasConceptScore W2765300930C112705442 @default.
• W2765300930 hasConceptScore W2765300930C126322002 @default.
• W2765300930 hasConceptScore W2765300930C176947019 @default.
• W2765300930 hasConceptScore W2765300930C2776938444 @default.
• W2765300930 hasConceptScore W2765300930C2777014857 @default.
• W2765300930 hasConceptScore W2765300930C2777288759 @default.
• W2765300930 hasConceptScore W2765300930C2908647359 @default.
• W2765300930 hasConceptScore W2765300930C501593827 @default.
• W2765300930 hasConceptScore W2765300930C64778159 @default.
• W2765300930 hasConceptScore W2765300930C71924100 @default.
• W2765300930 hasConceptScore W2765300930C76318530 @default.
• W2765300930 hasConceptScore W2765300930C86803240 @default.
• W2765300930 hasConceptScore W2765300930C89423630 @default.
• W2765300930 hasConceptScore W2765300930C90924648 @default.
• W2765300930 hasConceptScore W2765300930C98274493 @default.
• W2765300930 hasConceptScore W2765300930C99454951 @default.
• W2765300930 hasIssue "3" @default.
• W2765300930 hasLocation W27653009301 @default.
• W2765300930 hasLocation W27653009302 @default.
• W2765300930 hasOpenAccess W2765300930 @default.
• W2765300930 hasPrimaryLocation W27653009301 @default.
• W2765300930 hasRelatedWork W1541103017 @default.
• W2765300930 hasRelatedWork W1967984016 @default.
• W2765300930 hasRelatedWork W1992577796 @default.
• W2765300930 hasRelatedWork W2110265450 @default.

• next